szmtag The evaluation of orphan drugs by the German Joint Federal Committee—an eight-year review (11.12.2020)
DÄ internationalArchive50/2020The evaluation of orphan drugs by the German Joint Federal Committee—an eight-year review

Correspondence

The evaluation of orphan drugs by the German Joint Federal Committee—an eight-year review

Dtsch Arztebl Int 2020; 117: 868-9. DOI: 10.3238/arztebl.2020.0868

Schulz, S; Passon, A M; Perleth, M; Kulig, M; Paschke, N; Matthias, K

For technical reasons, the English full text will be published approximately two weeks after the German print edition has been published.

1.Schulz S, Passon A, Kulig M, Perleth M, Matthias K: Studien bei seltenen Erkrankungen: eine deskriptive Analyse abgeschlossener Orphan Drug Bewertungen im Gemeinsamen Bundes­aus­schuss. Gesundheitswesen 2018; 80: e54–61 CrossRef
2.Gemeinsamer Bundes­aus­schuss: Verfahren der Nutzenbewertung nach § 35a SGB V. www.g-ba.de/bewertungsverfahren/nutzenbewertung/ (last accessed on 1 April 2020).
3.Vokinger KN, Kesselheim AS: Application of orphan drug designation to cancer treatments (2008–2017): a comprehensive and comparative analysis of the USA and EU. BMJ Open 2019; 9: e028634 CrossRef MEDLINE PubMed Central
4.Sarpatwari A, Kesselheim AS: Reforming the orphan drug act for the 21st Century. N Engl J Med 2019; 381: 106–8 CrossRef MEDLINE
5.Europäische Kommission: Proposal for a regulation of the European Parliament and of the Council on health technology assessment and amending directive 2011/24/EU. www.ec.europa.eu/health/sites/health/files/technology_assessment/docs/com2018_51final_en.pdf (last accessed on 4 June 2020).

Info

Article